Literature DB >> 3779899

Activation of the met oncogene in the human MNNG-HOS cell line involves a chromosomal rearrangement.

P R Tempest, B R Reeves, N K Spurr, A J Rance, A M Chan, P Brookes.   

Abstract

In this study it is demonstrated that the activated met gene, which was originally detected in the MNNG-HOS chemically transformed human cell line, is a chimeric gene formed by the joining together of two distinct regions of DNA. Rearrangement of cellular DNA in MNNG-HOS cells was demonstrated by Southern analyses, which showed that the MNNG-HOS cell line contained unique met-related DNA fragments that were not detected in the parental cell line, HOS. Chromosomal localization using a series of rodent-human hybrid cell lines showed that the 5' end of the activated met gene is derived from human chromosome 1, in contrast to the 3' end of met which has been previously localized to human chromosome 7. The chimeric gene is transcribed to produce a 5-kb mRNA that is encoded both by regions of the gene derived from chromosome 1 and by regions of the gene derived from chromosome 7. Karyotype analysis of HOS and MNNG-HOS cells has identified several marker chromosomes that involve translocations of chromosomes 1 and 7. The possible location of the activated met locus within these rearranged chromosomes is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3779899     DOI: 10.1093/carcin/7.12.2051

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

1.  Analysis of the transgenome of MET transfectant cell lines reveals that MET activation is accompanied by an interstitial insertion.

Authors:  P J Scambler; B Wainwright; M Ramsay; M Farrall; G Bates; M F Ho; C Cooper
Journal:  Hum Genet       Date:  1990-02       Impact factor: 4.132

2.  The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.

Authors:  N R Soman; P Correa; B A Ruiz; G N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 3.  Genetic markers on chromosome 7.

Authors:  L C Tsui
Journal:  J Med Genet       Date:  1988-05       Impact factor: 6.318

4.  Cellular alterations and modulation of protein expression in bitumen-challenged human osteoblast cells.

Authors:  Alka Dhondge; Subin Surendran; Muhil Vannan Seralathan; Pravin K Naoghare; Kannan Krishnamurthi; Sivanesan Saravana Devi; Tapan Chakrabarti
Journal:  Environ Sci Pollut Res Int       Date:  2012-04-19       Impact factor: 4.223

5.  Leukaemia mortality among relatives of cystic fibrosis patients.

Authors:  L N al-Jader; R R West; J A Holmes; L Meredith; M C Goodchild; P S Harper
Journal:  Arch Dis Child       Date:  1991-03       Impact factor: 3.791

6.  Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population.

Authors:  Yu Sun; Meng-Meng Tian; Li-Xin Zhou; Wei-Cheng You; Ji-You Li
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

7.  TPR-MET oncogenic rearrangement: detection by polymerase chain reaction amplification of the transcript and expression in human tumor cell lines.

Authors:  N R Soman; G N Wogan; J S Rhim
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

8.  Liprin-α4 is required for nickel induced receptor protein tyrosine phosphatase-leukocyte antigen related receptor F (RPTP-LAR) activity.

Authors:  Kathrin Kiok; Hong Sun; Hailey Clancy; Sutapa Bose; Thomas Kluz; Fen Wu; Max Costa
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

Review 9.  The role of non-ras transforming genes in chemical carcinogenesis.

Authors:  C S Cooper
Journal:  Environ Health Perspect       Date:  1991-06       Impact factor: 9.031

10.  Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells.

Authors:  T Crepaldi; A L Pollack; M Prat; A Zborek; K Mostov; P M Comoglio
Journal:  J Cell Biol       Date:  1994-04       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.